Therapeutic Use of a Receptor Mimic Probiotic Reduces Intestinal Shiga Toxin Levels in a Piglet Model of Hemolytic Uremic Syndrome

Date
2014-06-01
Authors
Hostetter, Shannon
Helgerson, Amy
Paton, James
Cornick, Nancy
Paton, Adrienne
Cornick, Nancy
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Authors
Research Projects
Organizational Units
Journal Issue
Series
Department
Veterinary PathologyVeterinary Microbiology and Preventive Medicine
Abstract

Hemolytic uremic syndrome (HUS) is a systemic and potentially fatal complication of gastroenteritis secondary to Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) infection characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal damage. Shiga toxin (Stx), the toxin principle in HUS, is produced locally within the gut following EHEC colonization and is disseminated via the vasculature. Clinical development of HUS currently has no effective treatment and is a leading cause of renal failure in children. Novel post-exposure therapies are currently needed for HUS; therefore, the purpose of this study was to investigate the efficacy of a Stx receptor mimic probiotic in a porcine model of HUS. Edema disease, an infection of swine caused by host adapted Shiga toxin-producing Escherichia coli (STEC) and mediated by Shiga toxin 2e (Stx2e), shares many pathogenic similarities to HUS. In this study, three-week old piglets were inoculated with STEC and 24 hours later treated twice daily with a probiotic expressing an oligosaccharide receptor mimic for Stx2e to determine if the probiotic could reduce intestinal toxin levels.

Comments

This article is from BMC Research Notes 7 (2014): 331, doi:10.1186/1756-0500-7-331. Posted with permission.

Description
Keywords
Citation
DOI
Collections